Skip to main content

Drug Interactions between Myrbetriq and Solurex LA

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

dexAMETHasone mirabegron

Applies to: Solurex LA (dexamethasone) and Myrbetriq (mirabegron)

Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein may decrease the plasma concentrations of mirabegron, which has been shown in vitro to be a substrate of the isoenzyme and efflux transporter. However, in vivo results indicate that these pathways may play a limited role in the overall elimination. In healthy study subjects, mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by less than 50% when a single 100 mg dose of mirabegron was administered following multiple dosing of rifampin 600 mg once daily. No dosage adjustment is recommended when mirabegron is administered in combination with rifampin and probably other CYP450 3A4/P-gp inducers.

References

  1. "Product Information. Myrbetriq (mirabegron)." Astellas Pharma US, Inc (2012):

Switch to consumer interaction data

Drug and food interactions

Minor

mirabegron food

Applies to: Myrbetriq (mirabegron)

Food reduces the oral absorption and bioavailability of mirabegron. According to the product labeling, administration of a 50 mg tablet with a high-fat meal decreased mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) by 45% and 17%, respectively, whereas administration with a low-fat meal decreased mirabegron Cmax and AUC by 75% and 51%, respectively. In phase 3 clinical studies demonstrating both safety and efficacy, mirabegron was administered without regards to food content and intake. Therefore, mirabegron can be taken with or without food at the recommended dosage.

References

  1. "Product Information. Myrbetriq (mirabegron)." Astellas Pharma US, Inc (2012):

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer